When are the near-term data releases due on TENX clinical trials

Tenaya Therapeutics (NASDAQ: TNYA) has several near-term data releases scheduled for its clinical trials, particularly for its gene therapy candidates TN-201 and TN-401, and its MyClimb natural history study.

Here's a summary of the anticipated data releases:

• TN-201 (MyPEAK-1 trial for MYBPC3-associated Hypertrophic Cardiomyopathy):

• Additional data from Cohort 1 was presented as a late-breaker at the American College of Cardiology (ACC) Scientific Sessions on March 31, 2025.1

• Initial Cohort 2 data and an update on Cohort 1 are anticipated in the fourth quarter of 2025.2

• A company presentation before year-end 2025 is expected to discuss TN-201 data from the AHA Scientific Sessions and the MyPEAK-1 trial status.3

• TN-401 (RIDGE-1 trial for PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy):

• Initial data, including safety and post-dose biopsy results, from the first cohort (3E13 vg/kg dose) is anticipated in the second half of 2025.1

• Initial Cohort 1 data, focusing on safety and biopsy results for the first three patients, is expected in the fourth quarter of 2025.2

• A conference call was held on December 11, 2025, to discuss TN-401 data.4

• A company presentation before year-end 2025 is planned to share initial safety and biopsy data from the first three patients in RIDGE-1 Cohort 1.3

• MyClimb (pediatric non-interventional natural history study):

• Data is anticipated in the second half of 2025.1

• An abstract was accepted for presentation at the European Society of Cardiology (ESC) Annual Meeting, which took place from August 29 to September 1, 2025.2

These releases are key catalysts for Tenaya Therapeutics as they provide updates on the progress and potential efficacy of their gene therapy programs. Investors often monitor these announcements closely for insights into the company's pipeline development.